• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Septerna Inc.

    6/10/25 10:55:12 AM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SEPN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    Septerna, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    81734D104

    (CUSIP Number)


    05/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    81734D104


    1Names of Reporting Persons

    DRIEHAUS CAPITAL MANAGEMENT LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,659,911.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,659,911.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,659,911.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.46 %
    12Type of Reporting Person (See Instructions)

    IA

    Comment for Type of Reporting Person:  This amendment is being filed to reflect the change in our percentage of ownership of Septerna, Inc. (SEPN). DCM owned 10.46% of SEPN as of 5/31/2025, up from 7.03% of SEPN as of 3/31/2025


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Septerna, Inc.
    (b)Address of issuer's principal executive offices:

    250 East Grand Ave., Suite 65, South San Francisco, California, 94080
    Item 2. 
    (a)Name of person filing:

    Driehaus Capital Management LLC
    (b)Address or principal business office or, if none, residence:

    25 East Erie Street, Chicago, Illinois 60611
    (c)Citizenship:

    USA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    81734D104
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    4659911
    (b)Percent of class:

    10.46  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    4659911

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    4659911

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The shares reported by Driehaus Capital Management LLC (DCM) are held by numerous clients on a fully discretionary basis in accounts managed by DCM. Securities held in these clients' accounts are included in this report to reflect that DCM may have voting power and has dispositive power. To the best of DCM's knowledge, none of the referenced clients have the right to receive dividends or direct proceeds from the sale of interests relating to more than 5% of the class.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    DRIEHAUS CAPITAL MANAGEMENT LLC
     
    Signature:Janet McWilliams
    Name/Title:Janet McWilliams, General Counsel
    Date:06/10/2025
    Get the next $SEPN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SEPN

    DatePrice TargetRatingAnalyst
    6/23/2025$26.00Buy
    H.C. Wainwright
    2/18/2025$14.00Overweight → Equal Weight
    Wells Fargo
    11/19/2024$38.00Overweight
    Analyst
    11/19/2024Buy
    TD Cowen
    11/19/2024$43.00Overweight
    Wells Fargo
    11/19/2024$50.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $SEPN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Septerna with a new price target

    H.C. Wainwright initiated coverage of Septerna with a rating of Buy and set a new price target of $26.00

    6/23/25 8:09:11 AM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Septerna downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Septerna from Overweight to Equal Weight and set a new price target of $14.00

    2/18/25 8:55:10 AM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Analyst initiated coverage on Septerna with a new price target

    Analyst initiated coverage of Septerna with a rating of Overweight and set a new price target of $38.00

    11/19/24 7:39:27 AM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SEPN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ezekowitz Alan bought $92,270 worth of shares (13,319 units at $6.93), increasing direct ownership by 13% to 117,420 units (SEC Form 4)

    4 - Septerna, Inc. (0001984086) (Issuer)

    3/10/25 4:18:19 PM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ezekowitz Alan bought $515,934 worth of shares (86,681 units at $5.95), increasing direct ownership by 498% to 104,101 units (SEC Form 4)

    4 - Septerna, Inc. (0001984086) (Issuer)

    3/6/25 9:02:51 PM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and President Finer Jeffrey bought $96,961 worth of shares (17,000 units at $5.70), increasing direct ownership by 2% to 771,907 units (SEC Form 4)

    4 - Septerna, Inc. (0001984086) (Issuer)

    2/27/25 6:53:01 PM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SEPN
    SEC Filings

    View All

    Septerna Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Septerna, Inc. (0001984086) (Filer)

    9/3/25 7:00:21 AM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Septerna Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Septerna, Inc. (0001984086) (Filer)

    8/21/25 8:33:01 AM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Septerna Inc.

    10-Q - Septerna, Inc. (0001984086) (Filer)

    8/11/25 4:11:42 PM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SEPN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Biological Sciences Klein Uwe exercised 23,008 shares at a strike of $4.10 (SEC Form 4)

    4 - Septerna, Inc. (0001984086) (Issuer)

    8/19/25 5:02:20 PM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief People Officer Shaikhly Samira

    4 - Septerna, Inc. (0001984086) (Issuer)

    8/11/25 7:11:23 PM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by President and COO Bhatt Elizabeth

    4 - Septerna, Inc. (0001984086) (Issuer)

    8/11/25 7:09:59 PM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SEPN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Septerna to Participate in Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following upcoming investor conferences in September: Cantor Global Healthcare Conference 2025 Presentation on Wednesday, September 3, 2025, at 11:30 a.m. ET 2025 Wells Fargo Healthcare ConferenceFireside chat on Friday, September 5, 2025, at 8:45 a.m. ET Live webcasts of the presentations will be available in the investors section of the company's website at www.septerna.com. Replays will be archived for at least 30 days f

    8/27/25 8:00:00 AM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases

    SOUTH SAN FRANCISCO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the dosing of the first participants in its Phase 1 clinical trial of SEP-631, a selective oral small molecule Mas-related G protein-coupled receptor X2 (MRGPRX2) negative allosteric modulator (NAM) being developed for the treatment of chronic spontaneous urticaria (CSU) and other mast cell-driven diseases. The Phase 1 single-ascending dose (SAD) and multiple-ascending dose (MAD) clinical trial will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodyna

    8/21/25 8:00:00 AM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results

    Advancing Selection of Next-Generation Oral Small Molecule PTH1R Agonist for Clinical Development Initiating Phase 1 Trial for SEP-631, MRGPRX2 NAM Program, for Mast Cell Diseases Updated Cash Runway Expected to Support Operating Plans at Least into 2029 SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today highlighted key business updates and upcoming milestones and reported financial results for the second quarter ended June 30, 2025.   "We are executing effectively across our portfolio, with each program nearing important milestones," said Je

    8/11/25 4:01:00 PM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SEPN
    Leadership Updates

    Live Leadership Updates

    View All

    Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer

    SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotech company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Gil Labrucherie, CFA, J.D., as Chief Financial Officer. Mr. Labrucherie is a seasoned biopharma executive with more than 25 years of senior leadership experience in finance and legal roles for public biopharmaceutical and technology companies. "We are excited to welcome Gil to the team," said Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna. "His extensive expertise leading public company finance and capital strategy will be ins

    1/6/25 7:00:00 AM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SEPN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Septerna Inc.

    SC 13D - Septerna, Inc. (0001984086) (Subject)

    11/4/24 4:39:38 PM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Septerna Inc.

    SC 13G - Septerna, Inc. (0001984086) (Subject)

    11/4/24 4:15:38 PM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Septerna Inc.

    SC 13G - Septerna, Inc. (0001984086) (Subject)

    11/1/24 4:27:45 PM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care